FDA approves prescription nasal spray for opioid overdose treatment
Betsy Goodfellow | May 23, 2023 | News story | Medical Communications | FDA, Nasal Spray, Opvee, Poisoning and drug dependency, opioids, overdose
The US Food and Drug Administration (FDA) has announced that it has approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of opioid overdose in adults and paediatric patients over the age of 12.
The drug, when administered quickly, can reverse the effects of opioid overdose, including respiratory depression, sedation and low blood pressure, with this product providing 2.7mg of nalmefene into the nasal cavity. It is available by prescription and intended for use in healthcare and community settings.
Opvee’s approval follows various safety and pharmacokinetic studies, as well as a study which assessed how fast the drug worked in people who use opioids recreationally. Some adverse reactions were reported, these included nasal discomfort, headaches, nausea, dizziness, hot flushes, vomiting, anxiety, fatigue, nasal congestion and throat irritation, pain in the nose, decreased appetite, skin redness and excessive sweating.
It was also noted that the use of nalmefene hydrochloride in patients who are opioid depended can result in opioid withdrawal, including symptoms such as body aches, diarrhoea, fast heart rate, runny nose, fever, sneezing, goosebumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness and increased blood pressure.
Robert M Callif, MD, FDA commissioner, commented: “The agency continues to advance the FDA Overdose Prevention Framework and take actionable steps that encourage harm reduction by supporting the development of novel overdose reversal products. On the heels of the FDA’s recent approval of the first over-the-counter opioid reversal agent, the availability of nalmafene nasal spray places a new prescription opioid reversal option in the hands of communities, harm reduction groups and emergency responders.”
Betsy Goodfellow
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …
